公开(公告)号：US11142546B2

公开(公告)日：2021-10-12

申请号：US16090726

申请日：2017-03-23

Applicant: Research Triangle Institute

Inventor： Scott Runyon ,  Carla Hassler ,  Craig Shiner ,  Sanju Narayanan

IPC: C07K5/02 ,  C07K5/065 ,  A61K31/4015 ,  A61K31/55 ,  C07D207/416 ,  A61K31/495 ,  A61P25/20 ,  C07C237/24 ,  A61P25/30 ,  C07D211/60 ,  C07D223/20 ,  C07K11/00 ,  A61K38/00

Abstract: Neuropeptide S receptor agonists are provided. The NPS agonists include peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The molecules may be useful in the treatment of disorders, syndromes and conditions mediated by modulation of the neuropeptide S receptor such as substance abuse, narcolepsy, insomnia, obesity, cognitive decline, dementia, Alzheimer's disease, panic disorder, generalized anxiety, PTSD, phobias, schizophrenia and as supportive medication during any kind of cessation program in cognitive behavioral therapy, such as drug addiction, eating disorders and gambling.

公开(公告)号：US20150057268A1

公开(公告)日：2015-02-26

申请号：US14363079

申请日：2012-12-06

Applicant: RESEARCH TRIANGLE INSTITUTE

Inventor： Scott Runyon ,  Yanan Zhang ,  Carla Hassler ,  Brian Gilmour

IPC: C07D491/048 ,  C07D491/107

CPC classification number: C07D491/048 ,  C07D491/04 ,  C07D491/10 ,  C07D491/107

Abstract: Neuropeptide S receptor antagonists are provided that bind in functional assays to neuropeptide S receptors; methods are provided for use of these antagonists in treatment of conditions or disease states that are ameliorated by blocking of the neuropeptide S receptor, including substance abuse and substance abuse relapse; and for use of neuropeptide S receptor antagonists in the manufacture of therapeutics and pro-drugs for therapeutics useful in disease states and conditions sensitive to binding of the neuropeptide S receptor.

Abstract translation: 提供神经肽S受体拮抗剂，其在功能测定中与神经肽S受体结合; 提供了这些拮抗剂用于治疗通过阻断神经肽S受体而改善的病症或疾病状态的方法，包括药物滥用和药物滥用复发; 并且用于神经肽S受体拮抗剂在制备用于治疗疾病状态和治疗神经肽S受体结合敏感的疾病状态的治疗剂的前药中的用途。

公开(公告)号：US09150582B2

公开(公告)日：2015-10-06

申请号：US14363079

申请日：2012-12-06

Applicant: RESEARCH TRIANGLE INSTITUTE

Inventor： Scott Runyon ,  Yanan Zhang ,  Carla Hassler ,  Brian Gilmour

IPC: C07D491/04 ,  A61K31/4355 ,  C07D491/048 ,  C07D491/10 ,  C07D491/107

CPC classification number: C07D491/048 ,  C07D491/04 ,  C07D491/10 ,  C07D491/107

Abstract: Neuropeptide S receptor antagonists are provided that bind in functional assays to neuropeptide S receptors; methods are provided for use of these antagonists in treatment of conditions or disease states that are ameliorated by blocking of the neuropeptide S receptor, including substance abuse and substance abuse relapse; and for use of neuropeptide S receptor antagonists in the manufacture of therapeutics and pro-drugs for therapeutics useful in disease states and conditions sensitive to binding of the neuropeptide S receptor.

Abstract translation: 提供神经肽S受体拮抗剂，其在功能测定中与神经肽S受体结合; 提供了这些拮抗剂用于治疗通过阻断神经肽S受体而改善的病症或疾病状态的方法，包括药物滥用和药物滥用复发; 并且用于神经肽S受体拮抗剂在制备用于治疗疾病状态和治疗神经肽S受体结合敏感的疾病状态的治疗剂的前药中的用途。

公开(公告)号：US11220526B2

公开(公告)日：2022-01-11

申请号：US16090728

申请日：2017-03-23

Applicant: Research Triangle Institute ,  The Regents of the University of California

Inventor： Scott Runyon ,  Danni Harris ,  Rainer Reinscheid ,  Yanyan Zhang ,  Carla Hassler

IPC: C07K5/068 ,  A61K38/00 ,  C07K5/083 ,  C07K5/087 ,  C07K5/097 ,  C07K5/08 ,  C07K5/103 ,  C07K7/06 ,  C07K5/107 ,  A61P25/28 ,  A61P25/30 ,  A61P3/04 ,  A61P25/18

Abstract: Neuropeptide S receptor agonists are provided. The NPS agonists include trimeric, tetrameric, pentameric or hexameric peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The peptidomimetic molecules may be useful in the treatment of disorders, syndromes and conditions mediated by modulation of the neuropeptide S receptor such as substance abuse, narcolepsy, insomnia, obesity, cognitive decline, dementia, Alzheimer's disease, panic disorder, generalized anxiety, PTSD, phobias, schizophrenia and as supportive medication during any kind of cessation program in cognitive behavioral therapy, such as drug addiction, eating disorders and gambling.